Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

NCT05003700 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: Hepatic arterial infusion chemotherapy
DRUG: Lenvatinib
DRUG: Camrelizumab

Sponsor

Nanfang Hospital, Southern Medical University